2013
DOI: 10.1007/s00726-013-1567-0
|View full text |Cite
|
Sign up to set email alerts
|

Design and synthesis of a reagent for solid-phase incorporation of the phosphothreonine mimetic (2S,3R)-2-amino-3-methyl-4-phosphonobutyric acid (Pmab) into peptides in a bio-reversible phosphonyl-bis-pivaloyloxymethyl (POM) prodrug form

Abstract: Reported herein are the synthesis and solid-phase peptide incorporation of N-Fmoc-(2S,3R)-2-amino-3-methyl-4-phosphonobutyric acid bis-pivaloyloxymethyl phopshoryl ester [Fmoc-Pmab(POM)2-OH, 2] as a phosphatase-stable phosphothreonine (pThr) mimetic bearing orthogonal protection suitable for the synthesis of Pmab-containing peptides having bio-reversible protection of the phosphonic acid moiety. This represents the first report of a bio-reversibly protected pThr mimetic in a form suitable for facile solid-phas… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
4
0

Year Published

2014
2014
2020
2020

Publication Types

Select...
4
1

Relationship

1
4

Authors

Journals

citations
Cited by 6 publications
(4 citation statements)
references
References 28 publications
0
4
0
Order By: Relevance
“…13), appeared to be potent effectors of this cell cycle regulatory protein and may serve as a tool to study its role in cancerogenesis. [62][63][64][65] Masking the phosphonate moiety of peptide 43 by esterase labile pivaloyloxymethyl groups provided interesting prodrug. 63 The major challenge in the studies on these mimetics is their synthesis.…”
Section: Peptides With Non-hydrolysable Analogues Of Phosphoamino Acidsmentioning
confidence: 99%
See 1 more Smart Citation
“…13), appeared to be potent effectors of this cell cycle regulatory protein and may serve as a tool to study its role in cancerogenesis. [62][63][64][65] Masking the phosphonate moiety of peptide 43 by esterase labile pivaloyloxymethyl groups provided interesting prodrug. 63 The major challenge in the studies on these mimetics is their synthesis.…”
Section: Peptides With Non-hydrolysable Analogues Of Phosphoamino Acidsmentioning
confidence: 99%
“…This compound was asymmetrically reduced using chiral catalyst and nally converted into compound 48 suitable for introduction into peptide chain. 64 Preparation of the desired peptides was achieved easily by using classical procedures of both liquid-and solid-phase peptide syntheses.…”
Section: Peptides With Non-hydrolysable Analogues Of Phosphoamino Acidsmentioning
confidence: 99%
“…This prodrug exhibited approximately a 20-fold increase in activity over the free acid [233]. A recent report on phosphothreonine analogs targeted towards Plk1 also has relied upon a bis-POM strategy [234]. …”
Section: Current Applications Of Prodrug Technologymentioning
confidence: 99%
“…Functionalization via covalent grafting of organic functional groups allows POMs to tune their redox ability, acidity, and solubility, together with a potential modulation of essential features, e.g., stability, bioavailability, and recognition capability. , A lot of POMs containing compounds have been prepared with POMs retaining their structural integrity, including organonitrogen, organosilyl, organophosphonyl, and oxocarbon derivatives of POMs. The heteropolytungstates [α 2 -P 2 W 17 O 61 (SnR)] 7 has been reported with an alkyltin group with promising antitumor activities .…”
Section: Introductionmentioning
confidence: 99%